Clinical Trials: Crohn's Disease

Alabama

Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Birmingham; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Birmingham; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Birmingham; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Mobile; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Mobile; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Pell City; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Arizona

Oro Valley; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Tucson; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tucson; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Arkansas

Fayetteville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

California

Garden Grove; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

La Jolla; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

La Jolla; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Oceanside; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Oceanside; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Orange; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Palo Alto; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Palo Alto; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Roseville; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

San Francisco; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Colorado

Colorado Springs; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Golden; Rocky Mountain Clinical Research, Inc.
Active Crohn's Disease: International, Multicenter, Double-Blind, Placebo-controlled study for moderate to severe Crohn's Disease.

Golden; Rocky Mountain Clinical Research, Inc.
An investigational research trial to assess the safety and efficacy of a study drug in patients with active Crohn's disease.

Golden; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Golden; Rocky Mountain Clinical Research
Clinical Trial of CCX282-B in Individuals With Moderately to Severely Active Crohn’s Disease.

Golden; Rocky Mountain Clinical Research, Inc.
A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects with Moderately Active Crohn’s Disease.

Lakewood; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Lakewood; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lakewood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Wheat Ridge; Western States Clinical Research, Inc.
New Research Takes Aim At Crohn's Disease

Wheat Ridge; Western States Clinical Research, Inc.
Crohn's Disease Clinical Research Study

Connecticut

Waterbury; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Waterbury; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Florida

Clearwater; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Gainesville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Gainesville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Hialeah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Hollywood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jacksonville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New Port Richey; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

North Miami Beach; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

North Miami Beach; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

North Miami Beach; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Palm Harbor; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Sarasota; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Sarasota; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

St. Petersburg; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

St. Petersburg; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

St. Petersburg; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Winter Park; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Winter Park; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Winter Park; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Georgia

Marietta; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Marietta; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Marietta; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Savannah; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Savannah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Illinois

Chicago; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Chicago; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lombard; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Indiana

Bloomington; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Bloomington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Iowa

Davenport; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Davenport; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Kansas

Topeka; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Topeka; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Wichita; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Kentucky

Bowling Green; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Bowling Green; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lexington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lexington; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?

Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?

Lexington; University of Kentucky Chandler Medical Center
Relatives of Inflammatory Bowel Disease Patients Needed for Health Questionnaire

Louisville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Louisville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Louisville; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Louisiana

Metairie; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Metairie; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Metairie; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Metairie; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Monroe; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Maryland

Annapolis; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Annapolis; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Annapolis; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Chevy Chase; Chevy Chase Clinical Research/Metropolitan Gastroenterology Group
Crohn's Disease - Working for a Better Tomorrow

Chevy Chase; Metropolitan Gastroenterology Group/Chevy Chase Clinical Research
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Laurel; Maryland Digestive Disease Research, LLC
Crohn's Disease

Prince Frederick; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Townson; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Massachusetts

Newton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

West Yarmouth; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Worcester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Michigan

Chesterfield; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Chesterfield; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Dearborn; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Dearborn; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Troy; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Troy; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Minnesota

Minneapolis; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Minneapolis; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Rochester; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Rochester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mississippi

Ocean Springs; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Ocean Springs; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Missouri

Kansas City; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Kansas City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mexico; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Mexico; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

New Jersey

Cedar Knolls; Gastroenterology Research Associates, LLC
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Egg Harbor Township; Atlantic Gastroenterology Associates
Do you suffer from Crohn's disease and have been unable to find a successful treatment option?

Egg Harbor Township; Atlantic Gastroenterology Associates
Do you have Crohn's Disease?

Egg Harbor Township; Atlantic Gastroenterology Associates
Do You Have Crohn's Disease? Have You Received Infliximab (Remicade) Therapy?

New York

Great Neck; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Manhasset; Biomedical Research Alliance of New York
Crohn’s Disease - Adults

Manhasset; Biomedical Research Alliance of New York
Activated Charcoal as an Aid in Treating Crohn’s Disease

Mineola; Winthrop University Hospital Clinical Trials Center
This is a clinical research study for people with active moderate Crohn’s Disease.

Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a pediatric Crohn’s Disease research study.

New Hyde; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

New Hyde Park; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New Hyde Park; Biomedical Research Alliance of New York
Crohn’s Disease- Ages 6-17 years old

New York; Mount Sinai Medical Center
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease.
Protocol M02-403

New York; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

New York; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New York; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

New York; Mount Sinai Medical Center
A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor(TNF) over 26 weeks in patients suffering from Crohn's disease with prior loss of response or intolerance to infliximab.[RPCE05F1501]

New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn's Disease

New York; Mount Sinai Medical Center
Double-blind, Randomized, Multicenter, Placebo controlled Phase II Study of Efficacy and Safety of HMPL 004 in Subjects with Active Moderate Crohn's Disease [200500401]

New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn?Æs Disease

Syracuse; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Syracuse; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

North Carolina

Chapel Hill; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Chapel Hill; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Charlotte; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Charlotte; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Raleigh; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Raleigh; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Raleigh; Wake Research Associates
Don’t let Crohn’s Disease keep you from your favorite activities

Raleigh; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Raleigh; Wake Research Associates
Research Study for Crohn's Disease

Raleigh; Wake Research Associates
Do you have suffer from Crohn's Disease?

Raleigh; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Raleigh; Wake Research Associates
Do you have Crohn's Disease?

Wilmington; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

North Dakota

Fargo; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Fargo; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Ohio

Beachwood; Gastroenterology Associates of Cleveland, Inc.
Humira for Crohn's Disease

Beachwood; Gastroenterology Associates of Cleveland, Inc.
Research trial now enrolling for Humira ® for Crohn's Disease

Cincinnati; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Cincinnati; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cincinnati; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Cleveland; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Cleveland; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Cleveland; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cleveland; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Cleveland; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Dayton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Dayton; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Oklahoma

Oklahoma City; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Tulsa; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Tulsa; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tulsa; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Oregon

Portland; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Pennsylvania

Beaver Falls; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Beaver Falls; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Lancaster; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

South Carolina

Columbia; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Columbia; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Simpsonville; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Tennessee

Germantown; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Germantown; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Memphis; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Nashville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Nashville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Texas

Austin; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Austin; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Galveston; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Houston; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Houston; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Houston; Research Site
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease

Irving; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Irving; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

San Antonio; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tyler; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Utah

Salt Lake City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Salt Lake City; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Vermont

Burlington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Burlington; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Virginia

Charlottesville; University of Virginia
Men and women 18-65 with active Crohn's disease wanted for study

Chesapeake; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Chesapeake; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Norfolk; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Richmond; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Richmond; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Washington

Seattle; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Seattle; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Spokane; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Spokane; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tacoma; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tacoma; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Wisconsin

Madison; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Madison; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Milwaukee; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Milwaukee; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Monroe; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Monroe; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

International

Parkville, VIC, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bonheiden, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Brussels, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Gent, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Leuven, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Liege, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Roeselare, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Abbotsford, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Abbottsford, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Calgary, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Calgary, Alberta, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Edmonton, Alberta, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Edmonton, Alberta, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

London, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

London, Ontario, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Saskatoon, Saskatchewan, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Saskatoon, Saskatchewan, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Winnipeg, Manitoba, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Winnipeg, Manitoba, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Tallin, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tartu, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Jyvaskylä, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Mikkeli, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Frankfurt, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Heidelberg, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Heidleberg, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Jena, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Jena, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.

Magdeburg, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Ulm, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Heraclion, Crete, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Ioannina, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Piraeus, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Gyor, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Nagykanizsa, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Szeged, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Szombathely, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Haifa, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Kfar Saba, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Petha Tikva, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Rehovot, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Tel Aviv, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Valmiera, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Christchurch, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Hamilton, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Newton, Wellington, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Cluj Napoca, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease

Constanta, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease